Mass Tort brief
Mass Tort: Multi-Billion PFAS and Glyphosate Payouts Advance as Year-End Deadlines Loom
3M's $7.35B firefighter cancer pact and Bayer's nearing Roundup approval anchor a week of pivotal class action deadlines and bellwether settlements.
Mass Tort
3M's $7.35B settlement resolves 120,000 firefighter cancer claims — capping its biggest remaining toxic-tort threat before juries could assign punitive damages.
BackgroundAqueous film-forming foam used by airport and military firefighters contains per- and polyfluoroalkyl substances that accumulate permanently in the human body. Federal multidistrict litigation consolidated thousands of lawsuits alleging PFAS exposure causes kidney, testicular, and thyroid cancers.
- The master agreement carries a present value of $5.8B and covers six qualifying conditions, including kidney and testicular cancers.
- District Judge Richard Gergel issued case management orders setting a November 13 registration deadline for eligible claimants in MDL 2873.
- 3M affirmed it admits no liability and will absorb a $5.8B pre-tax charge in the fourth quarter without altering underlying financial targets.
Mass Tort
Mass Tort
Judicial sign-off on Bayer's $7.25B settlement before Christmas would resolve 65,000 cases — finally drawing a financial boundary around Monsanto's inherited glyphosate crisis.
BackgroundBayer acquired Monsanto in 2018 for $63B, inheriting tens of thousands of product liability lawsuits alleging exposure to glyphosate weedkiller caused non-Hodgkin lymphoma. The company has paid out over $10B in earlier settlements while continuing to defend the herbicide's safety.
- The proposed settlement pending in St. Louis Circuit Court establishes nine injury compensation tiers paid out over a 21-year schedule.
- Anderson noted that many plaintiffs who initially opted out are seeking to rejoin, diminishing the risk of Bayer walking away from the deal.
- Final judicial approval would significantly reduce Bayer's lingering US litigation liabilities, though objector appeals from holdout firms could delay distribution.
Mass Tort
Chicago's November 16 expert deadline tests whether epidemiological cancer links survive Rule 702 scrutiny — determining whether 12,000 hair relaxer lawsuits reach juries or collapse.
BackgroundLawsuits allege that chemical hair straightening products manufactured by L'Oréal and Revlon contain endocrine-disrupting phthalates that cause uterine and ovarian cancers. Federal judges must evaluate whether scientific expert testimony meets admissibility thresholds under Federal Rule of Evidence 702.
- Judge Mary Rowland scheduled the first federal bellwether trial from a finalized 5-case pool to begin in September 2027.
- Parties face a November 16 deadline for Daubert and summary judgment briefings challenging the scientific validity of epidemiological causation testimony.
- The pending judicial decision on expert reliability represents the primary hurdle determining whether cosmetics manufacturers face mass jury trials.
Mass Tort
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
